The global recombinant DNA technology market is expected to reach USD 844.6 billion by 2025, according to a new report by Grand View Research, Inc. Success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA (rDNA) technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.
Widespread successful application of this technique in veterinary product development, genetically modified crop development, bio pesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period.
Use of Genetically Modified (GM) products, such as GM animals, developed using rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess the GM products safety in context to its impact on human health and environment.
In addition, there is rising need to improve the recombinant proteins’ production capacity by several folds, owing to increase in demand for effective therapeutics for disease treatment. The aforementioned fact pronounces the technological advances in this sector thus driving growth.
As per Monsanto and other proponents of GM crops, genetic engineering is one of the fastest and widely adopted agricultural innovations over the past few years. This, in turn, is expected bolster the adoption of rDNA technology for non-traditional applications.
Full Research Report On Recombinant DNA Technology Market Analysis: www.grandviewresearch.com/industry-analysis/recombinant-dna-technology-market
Further key findings from the report suggest:
Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the global recombinant DNA technology market on the basis of product, component, application, end-use, and region:
Recombinant DNA Technology Product Outlook (Revenue, USD Million, 2014 – 2025)
Recombinant DNA Technology Component Outlook (Revenue, USD Million, 2014 – 2025)
Recombinant DNA Technology Application Outlook (Revenue, USD Million, 2014 – 2025)
Recombinant DNA Technology End-use Outlook (Revenue, USD Million, 2014 – 2025)
Recombinant DNA Technology Regional Outlook (Revenue, USD Million, 2014 – 2025)
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:28 2nd Street, Suite 3036 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/recombinant-dna-technology-market